StockMacro
Company, fund or insider

Help

Menu

Impact BioMedical

$6.17 -4.5% in 6 monthsMarket cap $53.3M

IBO on XASE, Health Care, Impact BioMedical, Inc., job postings

Measures activity, not value. Not investment advice.

Shares rose 130% in one month while a delisting notice landed and cash stands at just $21K.

  • WatchNet income of $1.6M over 12 months on just $38K revenue

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.

Industry
Pharmaceutical preparations (Health Care)
Employees
8
Website
impactbiomedinc.com
Listed
NYSE American, US
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $21K, net loss $645K.
Quarter to 30 Jun 2022: revenue $50K, net income -$799KQuarter to 30 Jun 2022: revenue $50K, net income -$799KQuarter to 30 Sep 2022: revenue $0, net income -$2.2MQuarter to 30 Sep 2022: revenue $0, net income -$2.2MQuarter to 31 Dec 2022: revenue $0, net income -$3.4MQuarter to 31 Dec 2022: revenue $0, net income -$3.4MQuarter to 31 Mar 2023: revenue –, net income -$849KQuarter to 30 Jun 2023: revenue –, net income -$1.1MQuarter to 30 Sep 2023: revenue –, net income -$1.2MQuarter to 31 Dec 2023: revenue –, net income -$1.3MQuarter to 31 Mar 2024: revenue –, net income -$998KQuarter to 30 Jun 2024: revenue –, net income -$884KQuarter to 30 Sep 2024: revenue –, net income $4.2MQuarter to 31 Mar 2025: revenue –, net income -$1.3MQuarter to 30 Jun 2025: revenue $7K, net income -$14.3MQuarter to 30 Jun 2025: revenue $7K, net income -$14.3MQuarter to 30 Sep 2025: revenue $18K, net income -$1.5MQuarter to 30 Sep 2025: revenue $18K, net income -$1.5MQuarter to 31 Dec 2025: revenue $7K, net income $5.2MQuarter to 31 Dec 2025: revenue $7K, net income $5.2MQuarter to 31 Mar 2026: revenue $7K, net income -$2.3MQuarter to 31 Mar 2026: revenue $7K, net income -$2.3MQuarter to 30 Jun 2026: revenue $3K, net income -$699KQuarter to 30 Jun 2026: revenue $3K, net income -$699KQuarter to 30 Sep 2026: revenue $21K, net income -$645KQuarter to 30 Sep 2026: revenue $21K, net income -$645K
30 Jun 2022RevenueNet incomeNet losstallest bar $14.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$21K-$645K
30 Jun 2026$3K-$699K
31 Mar 2026$7K-$2.3M
31 Dec 2025$7K$5.2M
30 Sep 2025$18K-$1.5M
30 Jun 2025$7K-$14.3M
31 Mar 2025–-$1.3M
30 Sep 2024–$4.2M
30 Jun 2024–-$884K
31 Mar 2024–-$998K
31 Dec 2023–-$1.3M
30 Sep 2023–-$1.2M
30 Jun 2023–-$1.1M
31 Mar 2023–-$849K
31 Dec 2022$0-$3.4M
30 Sep 2022$0-$2.2M
30 Jun 2022$50K-$799K
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $38K –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $1.6M -$44.2M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $21K $12K
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $22.9M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – $22.9M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.17
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. – 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. over 999 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 5.3 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Impact BioMedicalIBO (this company) $53.3M–over 999––
Citius OncologyCTOR $53.2Mloss–––
Xilio TherapeuticsXLO $53.4Mloss0.97+73%-20.9%
XBiotechXBIT $52.7Mloss–––
LifevantageLFVN $52.6M19.30.31-25%1.6%
Boundless BioBOLD $54.8Mloss–––

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$2K

bought $0, sold $2K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-18%

18 13F filers vs 22

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

3.5%

306K shares held by 13F filers (30 Sep 2026) of 8.6M outstanding (5 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.3%

25K shares sold short (30 Oct 2026) of 8.6M outstanding (5 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.1

25K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-6.4%

26K shares sold short in the report before, 25K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

42%

42% of off-exchange volume on 17 Nov 2026 was short sales; 1-year average 41%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

15

15 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

15 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $6.17 on 17 Nov 2026, +8.9% over 12 months (12-month range $2.68 to $9.84)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $148K in the last 12 months (the 12 months before: -$7.3M).
Revenue per quarter. Revenue $21K in the latest quarter, +17% on a year earlier.
Institutional holders (13F filers). 18 13F filers reported holding it in the latest 13F quarter, -14% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 17 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
18 Nov 20268-K and other filingsAll directors, CFO and COO resigned at Effective Time; Kanans Visvanats (Chairman) and seven others appointed PubCo directors
18 Nov 20268-K and other filingsCompleted merger; NYSE American asked to suspend trading before Nov 18, 2026 open and withdraw listing of common stock
18 Nov 20268-K and other filingsCompleted merger with PubCo's Nevada subsidiary and PubCo's acquisition of Zoar Labs, Nov 17, 2026; 8,640,000 PubCo shares issued
18 Nov 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 May 2026Sharp changeShort interest spike: short interest spike, 1.0M vs usual 269K (2026-04-30); 3.6x the same period a year earlier
28 Apr 2026Sharp changeShort interest spike: short interest spike, 1.2M vs usual 247K (2026-04-15); 9.8x the same period a year earlier
14 Apr 2026Sharp changeShort interest spike: short interest spike, 1.9M vs usual 236K (2026-03-31); 15.9x the same period a year earlier
31 Mar 2026Sharp changeShort interest spike: short interest spike, 1.3M vs usual 223K (2026-03-13); 146.4x the same period a year earlier
13 Mar 20258-K and other filingsDirector or officer change
13 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Oct 20248-K and other filingsDirector or officer change
8 Oct 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Aug 20248-K and other filingsRegistered new securities for sale (S-1)
20 Aug 20248-K and other filingsRegistered new securities for sale (S-1)
9 Aug 20248-K and other filingsRegistered new securities for sale (S-1)
11 Jun 20248-K and other filingsRegistered new securities for sale (S-1)
7 Jun 20248-K and other filingsDirector or officer change
7 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Feb 20248-K and other filingsRegistered new securities for sale (S-1)
21 Nov 20238-K and other filingsRegistered new securities for sale (S-1)
1 Nov 20238-K and other filingsRegistered new securities for sale (S-1)
17 Oct 20238-K and other filingsRegistered new securities for sale (S-1)
1 Aug 20238-K and other filingsRegistered new securities for sale (S-1)
24 Jul 20238-K and other filingsRegistered new securities for sale (S-1)
30 Jun 20238-K and other filingsRegistered new securities for sale (S-1)
21 Jun 20238-K and other filingsRegistered new securities for sale (S-1)
2 Jun 20238-K and other filingsRegistered new securities for sale (S-1)
15 May 20238-K and other filingsRegistered new securities for sale (S-1)
31 Jan 20238-K and other filingsRegistered new securities for sale (S-1)
9 Jan 20238-K and other filingsRegistered new securities for sale (S-1)
7 Dec 20228-K and other filingsRegistered new securities for sale (S-1)
24 Aug 20228-K and other filingsRegistered new securities for sale (S-1)
2 Aug 20228-K and other filingsRegistered new securities for sale (S-1)
11 Jul 20228-K and other filingsRegistered new securities for sale (S-1)
24 Jun 20228-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Sep 2024: $156K published
Month from 1 Nov 2024: -$17K published
Month from 1 Dec 2024: $5K published
Month from 1 Mar 2025: -$2.2M published
Month from 1 Apr 2025: -$5.1M published
Month from 1 May 2025: -$88K published
Month from 1 Jan 2026: -$88K published
Month from 1 Mar 2026: -$58K published
Month from 1 Sep 2026: -$2K published
Revenue per quarter
Quarter ended 30 Jun 2022: $50K; public on 6 Oct 2023
Quarter ended 30 Sep 2022: $0; public on 14 Nov 2023
Quarter ended 31 Dec 2022: $0; public on 21 Feb 2024
Quarter ended 30 Jun 2025: $7K; public on 15 Aug 2025
Quarter ended 30 Sep 2025: $18K; public on 8 Nov 2025
Quarter ended 31 Dec 2025: $7K; public on 12 Mar 2026
Quarter ended 31 Mar 2026: $7K; public on 13 May 2026
Quarter ended 30 Jun 2026: $3K, -57% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $21K, +17% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
30 Sep 2024 report: 7; public on 14 Nov 2024
31 Dec 2024 report: 10; public on 14 Feb 2025
31 Mar 2025 report: 16; public on 15 May 2025
30 Jun 2025 report: 17; public on 14 Aug 2025
30 Sep 2025 report: 21; public on 14 Nov 2025
31 Dec 2025 report: 24; public on 17 Feb 2026
31 Mar 2026 report: 20; public on 15 May 2026
30 Jun 2026 report: 22; public on 14 Aug 2026
30 Sep 2026 report: 18; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is net change in 13F-reported shares at -3.5M (30 Sep 2026), 2988% below its normal reading of 122K; higher than 11% of its own history.
  • Insider net buying (open market): Insiders sold a net $148K in the last 12 months (the 12 months before: -$7.3M).
  • Revenue per quarter: Revenue $21K in the latest quarter, +17% on a year earlier.
  • Institutional holders (13F filers): 18 13F filers reported holding it in the latest 13F quarter, -14% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 18 insider trades

Last 90 days: 1 sale, $2K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
24 Sep 2026DSS, Inc.10% ownerSell906$1.86$2KForm 4
30 Mar 2026Todd D MackoChief Financial OfficerSell45,000$0.56$25KForm 4
25 Mar 2026Jason GradyDirectorSell50,000$0.65$32KForm 4
6 Jan 2026DSS, Inc.10% ownerSell161,000$0.55$88KForm 4
27 May 2025DSS, Inc.10% ownerSell161,000$0.55$88KForm 4
7 Apr 2025DSS, Inc.10% ownerSell890,800$0.95$846KForm 4
7 Apr 2025Heng Fai Ambrose ChanDirectorSell351,555$0.50$176KForm 4
4 Apr 2025Alset Inc. and 2 others10% ownerSell1,689,693$0.66$1.1MForm 4

18 institutions reported shares at the end of Q3 2026, 4% of the shares outstanding; 1 opened a position, 6 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Geode Capital Management, LLC94K1.09%$526K-1.1M-92%
Vanguard Capital Management LLC74K0.85%$413K-735K-91%
State Street Corp49K0.56%$273K-559K-92%
Vanguard Fiduciary Trust Co47K0.54%$262K-543K-92%
BlackRock, Inc.20K0.23%$112K-240K-92%
Northern Trust Corp19K0.22%$104K-217K-92%
Vanguard Global Advisers, LLC2,5510.03%$14K-30K-92%
Morgan Stanley7380.01%$4K-8,547-92%
UBS Group AG2990.00%$2K-2,101-88%
Global Trust Asset Management, LLC1440.00%$806-1,674-92%

Company events

All 37 company events

In 12 months: 1 major agreement, 1 completed deal, 1 delisting notice, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
18 Nov 2026All directors, CFO and COO resigned at Effective Time; Kanans Visvanats (Chairman) and seven others appointed PubCo directors; Completed merger with PubCo's Nevada subsidiary and PubCo's acquisition of Zoar Labs, Nov 17, 2026; 8,640,000 PubCo shares issued; Completed merger; NYSE American asked to suspend trading before Nov 18, 2026 open and withdraw listing of common stockSame filing: changed shareholder rights, change of control, changed its bylaws or fiscal year8-K
4 Mar 2026Signed a major agreement8-K
28 Jul 2025Signed a major agreement8-K
23 Jun 2025Signed a major agreement8-K
3 Apr 2025Signed a major agreement8-K
28 Mar 2025Signed a major agreement8-K
13 Mar 2025Director or officer change8-K
8 Oct 2024Director or officer change8-K
Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 18 Nov 2026Filings change

    filed a director or officer change: All directors, CFO and COO resigned at Effective Time; Kanans Visvanats (Chairman) and seven others appointed PubCo directors.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 18 Nov 2026Filings record

    All directors, CFO and COO resigned at Effective Time; Kanans Visvanats (Chairman) and seven others appointed PubCo directors

  3. 18 Nov 2026Filings record

    Completed merger; NYSE American asked to suspend trading before Nov 18, 2026 open and withdraw listing of common stock

  4. 18 Nov 2026Filings record

    Completed merger with PubCo's Nevada subsidiary and PubCo's acquisition of Zoar Labs, Nov 17, 2026; 8,640,000 PubCo shares issued

  5. 12 May 2026Short interest and volume change

    had 1.0M shares sold short in the 30 Apr 2026 report, 3.6× the same report last year.

    Same report last year: 283K; its normal report is 269K.

    See the evidence
    This period
    1.0M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    269K
    Typical spread (median absolute deviation)
    110K
    How far from its usual level
    +4.6
    Same report last year
    283K
    History used
    577 days
    2025-04-30: 283K2025-05-15: 601K2025-05-30: 347K2025-06-13: 254K2025-06-30: 667K2025-07-15: 308K2025-07-31: 164K2025-08-15: 213K2025-08-29: 316K2025-09-15: 346K2025-09-30: 233K2025-10-15: 151K2025-10-31: 154K2025-11-14: 152K2025-11-28: 99K2025-12-15: 84K2025-12-31: 331K2026-01-15: 288K2026-01-30: 239K2026-02-13: 141K2026-02-27: 152K2026-03-13: 1.3M2026-03-31: 1.9M2026-04-15: 1.2M2026-04-30: 1.0M
    the 30 Apr 2026 report24 earlier reportsnormal: 269K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 25 Apr 2026Short interest and volume change

    had 1.2M shares sold short in the 15 Apr 2026 report, 9.8× the same report last year.

    Same report last year: 123K; its normal report is 247K.

    See the evidence
    This period
    1.2M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    247K
    Typical spread (median absolute deviation)
    94K
    How far from its usual level
    +6.9
    Same report last year
    123K
    History used
    562 days
    2025-04-15: 123K2025-04-30: 283K2025-05-15: 601K2025-05-30: 347K2025-06-13: 254K2025-06-30: 667K2025-07-15: 308K2025-07-31: 164K2025-08-15: 213K2025-08-29: 316K2025-09-15: 346K2025-09-30: 233K2025-10-15: 151K2025-10-31: 154K2025-11-14: 152K2025-11-28: 99K2025-12-15: 84K2025-12-31: 331K2026-01-15: 288K2026-01-30: 239K2026-02-13: 141K2026-02-27: 152K2026-03-13: 1.3M2026-03-31: 1.9M2026-04-15: 1.2M
    the 15 Apr 2026 report24 earlier reportsnormal: 247K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 11 Apr 2026Short interest and volume change

    had 1.9M shares sold short in the 31 Mar 2026 report, 16× the same report last year.

    Same report last year: 120K; its normal report is 236K.

    See the evidence
    This period
    1.9M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    236K
    Typical spread (median absolute deviation)
    84K
    How far from its usual level
    +13.4
    Same report last year
    120K
    History used
    547 days
    2025-03-31: 120K2025-04-15: 123K2025-04-30: 283K2025-05-15: 601K2025-05-30: 347K2025-06-13: 254K2025-06-30: 667K2025-07-15: 308K2025-07-31: 164K2025-08-15: 213K2025-08-29: 316K2025-09-15: 346K2025-09-30: 233K2025-10-15: 151K2025-10-31: 154K2025-11-14: 152K2025-11-28: 99K2025-12-15: 84K2025-12-31: 331K2026-01-15: 288K2026-01-30: 239K2026-02-13: 141K2026-02-27: 152K2026-03-13: 1.3M2026-03-31: 1.9M
    the 31 Mar 2026 report24 earlier reportsnormal: 236K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 25 Mar 2026Short interest and volume change

    had 1.3M shares sold short in the 13 Mar 2026 report, 146× the same report last year.

    Same report last year: 9,001; its normal report is 223K.

    See the evidence
    This period
    1.3M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    223K
    Typical spread (median absolute deviation)
    84K
    How far from its usual level
    +8.8
    Same report last year
    9,001
    History used
    529 days
    2025-03-14: 9,0012025-03-31: 120K2025-04-15: 123K2025-04-30: 283K2025-05-15: 601K2025-05-30: 347K2025-06-13: 254K2025-06-30: 667K2025-07-15: 308K2025-07-31: 164K2025-08-15: 213K2025-08-29: 316K2025-09-15: 346K2025-09-30: 233K2025-10-15: 151K2025-10-31: 154K2025-11-14: 152K2025-11-28: 99K2025-12-15: 84K2025-12-31: 331K2026-01-15: 288K2026-01-30: 239K2026-02-13: 141K2026-02-27: 152K2026-03-13: 1.3M
    the 13 Mar 2026 report24 earlier reportsnormal: 223K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 25 Mar 2025Insiders record

    DSS, INC. (ten percent owner) bought 200 shares of IBO ($310) (dated 24 Mar 2025)

  10. 13 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 13 Mar 2025Filings record

    Director or officer change

  12. 10 Dec 2024Insiders record

    Heuszel Frank D (Chief Executive Officer) bought 500 shares of IBO ($1,130) (dated 9 Dec 2024)

  13. 4 Dec 2024Insiders record

    Heuszel Frank D (Chief Executive Officer) bought 1,050 shares of IBO ($2,742) (dated 3 Dec 2024)

  14. 4 Dec 2024Insiders record

    Heuszel Frank D (Chief Executive Officer) bought 500 shares of IBO ($1,305) (dated 3 Dec 2024)

  15. 8 Oct 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 8 Oct 2024Filings record

    Director or officer change

  17. 20 Sep 2024Insiders record

    DSS, INC. (ten percent owner) bought 1,000 shares of IBO ($2,330) (dated 19 Sep 2024)

  18. 19 Sep 2024Insiders record

    DSS, INC. (ten percent owner) bought 57,800 shares of IBO ($153,220) (dated 18 Sep 2024)

  19. 27 Aug 2024Filings record

    Registered new securities for sale (S-1)

  20. 20 Aug 2024Filings record

    Registered new securities for sale (S-1)

  21. 9 Aug 2024Filings record

    Registered new securities for sale (S-1)

  22. 11 Jun 2024Filings record

    Registered new securities for sale (S-1)

  23. 7 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 7 Jun 2024Filings record

    Director or officer change

  25. 28 Feb 2024Filings record

    Registered new securities for sale (S-1)

  26. 21 Nov 2023Filings record

    Registered new securities for sale (S-1)

  27. 1 Nov 2023Filings record

    Registered new securities for sale (S-1)

  28. 17 Oct 2023Filings record

    Registered new securities for sale (S-1)

  29. 1 Aug 2023Filings record

    Registered new securities for sale (S-1)

  30. 24 Jul 2023Filings record

    Registered new securities for sale (S-1)

  31. 30 Jun 2023Filings record

    Registered new securities for sale (S-1)

  32. 21 Jun 2023Filings record

    Registered new securities for sale (S-1)

  33. 2 Jun 2023Filings record

    Registered new securities for sale (S-1)

  34. 15 May 2023Filings record

    Registered new securities for sale (S-1)

  35. 31 Jan 2023Filings record

    Registered new securities for sale (S-1)

  36. 9 Jan 2023Filings record

    Registered new securities for sale (S-1)

  37. 7 Dec 2022Filings record

    Registered new securities for sale (S-1)

  38. 24 Aug 2022Filings record

    Registered new securities for sale (S-1)

  39. 2 Aug 2022Filings record

    Registered new securities for sale (S-1)

  40. 11 Jul 2022Filings record

    Registered new securities for sale (S-1)

Showing the newest 40 of 43 entries; narrow the window or the kind of data to see older ones.

Not listed: 37 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001834105
Ticker
IBO
Domain
impactbiomedinc.com
Hq location
NY|WEST HENRIETTA|14586 (1 unverified)
Name
Biolife Sugar, Inc, DSS Biolife International, Inc, DSS Biomedical International, Inc, Global BioLife, Inc and 6 more
  • SEC Form 13F institutional holdings81 data points30 Sep 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)54 records12 Feb 2021 to 18 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)215 data points31 Dec 2021 to 5 Nov 2026
  • SEC Form 4 insider transactions18 records, 60 data points18 Sep 2024 to 24 Sep 2026
  • FINRA short interest (twice monthly)152 data points30 Sep 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1090 data points17 Sep 2024 to 17 Nov 2026